Real-world questions and concerns about disease-modifying antirheumatic drugs (DMARDs): a retrospective analysis of questions to a medicine call center.
Hiba El MasriSamantha A HollingworthMieke L van DrielHelen BenhamTreasure M McGuirePublished in: BMC rheumatology (2020)
Consumers have considerable uncertainty regarding DMARDs and may overemphasise risk. Patients cautiously assess the benefits and risks of their DMARDs but when new treatments emerge, they tend to overestimate their effectiveness.